Financial Performance - The company's operating revenue for the first half of 2023 was ¥709,071,800.34, a decrease of 28.45% compared to ¥991,052,056.37 in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2023 was ¥143,137,171.51, down 35.23% from ¥221,005,894.53 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥104,222,388.72, a decline of 45.68% compared to ¥191,856,661.41 in the same period last year[12]. - The net cash flow from operating activities was ¥156,384,423.12, which is a decrease of 31.48% from ¥228,241,860.95 in the previous year[12]. - The basic earnings per share for the first half of 2023 was ¥0.1958, down 35.29% from ¥0.3026 in the same period last year[12]. - The diluted earnings per share for the first half of 2023 was ¥0.1958, a decrease of 35.25% compared to ¥0.3024 in the previous year[12]. - The weighted average return on equity was 2.07%, down 1.36% from 3.43% in the same period last year[12]. - The company reported a total non-recurring gains and losses amounting to CNY 38,914,782.79 for the reporting period[14]. - The company achieved operating revenue of CNY 709.07 million, a decrease of 28.45% year-on-year, primarily due to limited sales volume of products[31]. - The net profit attributable to shareholders was CNY 143.14 million, down 35.23% year-on-year, while the net profit excluding non-recurring gains and losses was CNY 104.22 million, a decline of 45.68%[31]. Market Overview - The blood products market in China is currently valued at over CNY 400 billion, with significant growth potential compared to mature markets in Europe and the US[16]. - The global blood products market is projected to exceed USD 47.7 billion by 2027, indicating a robust growth trajectory[16]. - The domestic market for immunoglobulin and coagulation factor products is expected to expand significantly due to increased clinical applications and broader insurance coverage[23]. - The average sales prices and per capita usage of blood products in developed countries are significantly higher than in China, suggesting room for growth as income levels rise[24]. - The blood products industry in China is characterized by long-term supply shortages, with strict regulations on imports and production[22]. - The blood products industry is experiencing increasing concentration, with the top five global companies holding over 80% market share, indicating a trend towards oligopoly[25]. - The Chinese blood products market is expected to exceed 100 billion yuan in capacity, driven by economic growth, aging population, and increased clinical demand[25]. Company Strategy and Operations - The company operates in a highly regulated industry with only 28 licensed blood product manufacturers in China, creating high entry barriers[19]. - The company anticipates that the number of newly approved plasma collection stations will increase, leading to a sustained rise in plasma collection volume in the future[22]. - The company is positioned to benefit from the tightening global supply of blood products, creating opportunities for domestic alternatives and exports[24]. - The company has established a strategic cooperation with Xinjiang Deyuan to supply no less than 180 tons of plasma annually, extending the cooperation period by one year[26]. - Following the acquisition of Paisfiko, the company now has a total of 11 product varieties, ranking among the top three in the domestic blood products industry[27]. - The company anticipates a plasma collection volume exceeding 1,000 tons in 2023, entering the first tier of blood products producers[27]. - The company’s product range includes 8 varieties of human blood albumin and immunoglobulins, addressing critical medical needs such as shock and immune deficiencies[28]. - The company’s strategic expansion includes both organic growth and mergers, enhancing its competitive position in the blood products market[26]. - The company is focused on developing new products and technologies to meet the increasing demand for blood products in China[25]. - The company’s strategic initiatives aim to leverage resources, technology, and scale advantages to further increase market share[25]. Financial Position and Assets - Total assets at the end of the reporting period were ¥8,087,290,606.54, an increase of 1.31% from ¥7,982,324,465.77 at the end of the previous year[12]. - The net assets attributable to shareholders at the end of the reporting period were ¥6,938,535,011.90, up 1.03% from ¥6,867,524,210.96 at the end of the previous year[12]. - Cash and cash equivalents decreased to ¥889,546,022.34, representing 11.00% of total assets, down from 12.54% at the end of the previous year[44]. - Accounts receivable decreased to ¥458,931,120.12, making up 5.67% of total assets, down from 10.47% year-over-year[44]. - Inventory increased to ¥891,048,288.09, accounting for 11.02% of total assets, up from 7.81% last year[44]. - The company has a total of ¥40,644.96 million in unutilized raised funds, including ¥38,120.85 million that remains unused[49]. - The company has established a special account for managing raised funds, ensuring compliance with regulations and protecting investor interests[48]. Environmental Compliance - The company is not listed as a key pollutant discharge unit by environmental protection authorities, ensuring compliance with environmental regulations[82]. - The company has not experienced any pollution incidents or disputes during the reporting period and has not faced administrative penalties for violating environmental laws[83]. - The company obtained a new pollutant discharge permit valid until September 5, 2027, demonstrating its commitment to environmental compliance[84]. - The company received environmental approval for the expansion project on May 18, 2023, from the Harbin New Area Management Committee[85]. - The company has a valid wastewater discharge permit until December 9, 2026, obtained on December 10, 2021[85]. - The company reported a total nitrogen concentration of 1.83 mg/L at the main discharge point, compliant with discharge standards[87]. - The biochemical oxygen demand (BOD) was recorded at 3.815 mg/L, adhering to the specified concentration limits[87]. - The chemical oxygen demand (COD) was measured at 20.745 mg/L, within the allowable limits[87]. - The company reported zero instances of exceeding pollution discharge standards across various pollutants[86][88]. - The company maintains a hydrogen sulfide concentration of 1.4 mg/Nm³, compliant with pharmaceutical industry air pollution standards[88]. Shareholder and Corporate Governance - The company emphasizes shareholder rights protection and maintains transparent communication with investors[102]. - The company will not distribute cash dividends or issue bonus shares for the half-year period[72]. - The participation rate in the 2023 first extraordinary general meeting was 54.43%[70]. - The company approved the 2020 stock option and restricted stock incentive plan, granting 1.815 million stock options and 1.815 million restricted shares to 41 incentive recipients on May 19, 2020[74]. - The company has not experienced significant changes in project feasibility[51]. - The company has not sold any significant assets during the reporting period[62]. - The company reported no significant litigation or arbitration matters during the reporting period[108]. - There were no major related party transactions or significant contracts during the reporting period[109][111]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to recover from the revenue decline experienced in the first half of 2023[143]. - The overall financial health of the company is under scrutiny, with management likely to implement new strategies to address the losses and improve profitability moving forward[156].

证券代码：000403 证券简称：派林生物 编号：【2023】003 □特定对象调研 □ 分析师会议 □媒体采访 □ 业绩说明会 投资者关系活 □新闻发布会 □ 路演活动 动类别 ☑现场参观 □其他 （请文字说明其他活动内容） 高毅资产、大家保险、人保资产、嘉实基金、湘财基金、太平基 金、中庚基金、泰康基金、广发基金、淳厚基金、招银理财、上 海大正投资、深圳市红筹投资、杭州恩宝资产、上海睿郡资产、 厦门汇元千方投资、上海冲积资产、深圳瑞文、北京橡果资产、 闻天私募、上海磐耀资产、国融证券自营、东方阿尔法基金、云 参与单位名称 南云投资本、上海彤源投资、恩泽投资、泽桐基金、鼎鑫资产、 及人员姓名 伏枥资本、盛弘资本、瑞氪投资、Snow Lake、VIP Research& Management Inc.、海通证券、野村东方、西南证券、中银国际、 开源证券、中信证券、安信证券、华福证券、光大证券、安信证 券、招商证券、东海证券、中信建投证券、国泰君安证券、兴业 证券、华创证券等 时间 2023 年 6 月 2 日 地点 哈尔滨 董事长 付绍兰 董事 杨莉 上市公司接待 副总经理 吴迪 人员姓名 副总经理 闫磊 董 ...

证券代码：000403 证券简称：派林生物 派斯双林生物制药股份有限公司投资者关系活动记录表 编号：【2023】002 □特定对象调研 □ 分析师会议 □媒体采访 ☑ 业绩说明会 投资者关系活 □新闻发布会 □ 路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 及人员姓名 采用网络远程的方式召开业绩说明会提问的股东及投资者 时间 2023 年 5 月 11 日 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 总经理 袁华刚 副总经理 吴迪 副总经理 杨彬 上市公司接待 董事会秘书 赵玉林 人员姓名 财务总监 王晔弘 证券事务代表兼投资者关系总监 邹叶丹 1、请问公司做大做强的具体方针和策略？ 公司坚守血液制品主业的基本原则一直以来没有变化，首先 投资者关系活 针对原料端，我们在保障原有浆站持续健康合规发展的同时，积 极采用新站开发和战略合作并举的方式，将持续提升上市公司旗 动主要内容介 下的整体供浆能力；在产品研发端，我们近年来新产品 ...

证券代码：000403 证券简称：派林生物 派斯双林生物制药股份有限公司投资者关系活动记录表 编号：【2023】001 □特定对象调研 □ 分析师会议 □媒体采访 ☑ 业绩说明会 投资者关系活 □新闻发布会 □ 路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 通过深圳证券交易所"互动易"平台"云访谈"栏目参加 2022 年 及人员姓名 度业绩说明会的股东及投资者 时间 2023 年 5 月 4 日 地点 深圳证券交易所"互动易"平台"云访谈"栏目 总经理 袁华刚 副总经理 吴迪 副总经理 杨彬 上市公司接待 董事会秘书 赵玉林 人员姓名 财务总监 王晔弘 证券事务代表兼投资者关系总监 邹叶丹 独立董事 何晴 独立财务顾问主办人 吴博 主要问答记录如下： 1、公司 2023 年一季度业绩下降的主要原因？全年是否可以 实现恢复？ 投资者关系活 公司 2023 年一季度收入及利润下降，主要是由于 2022 年下 动主要内容介 半年受疫情影响公司各地浆站遭遇反复关停，特别是新疆浆站停 绍 采时间较长，导致 2022 年四季度投浆量下降，使得 2023 年一季 度可售产品有限，较大程度影 ...

Group 1: Event Details - The company will participate in the "2023 Shanxi Listed Companies Investor Online Reception Day" on May 11, 2023, from 15:00 to 17:00 [1] - The event will be conducted online, accessible via the "Panorama Roadshow" website, WeChat public account, or the Panorama Roadshow APP [1] Group 2: Company Representatives - Attendees include General Manager Yuan Huagang, Vice General Managers Wu Di and Yang Bin, Board Secretary Zhao Yulin, CFO Wang Yehong, and Investor Relations Director Zou Yedan [1] Group 3: Communication Focus - The discussion will cover 2022 operating performance, corporate governance, development strategy, operational status, and sustainable development [1] - Investors are encouraged to actively participate in the interaction [1]

Financial Performance - The company's operating revenue for 2022 was ¥2,405,188,425.37, an increase of 21.98% compared to ¥1,971,734,315.85 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥587,131,491.86, representing a growth of 50.14% from ¥391,063,978.44 in 2021[12]. - The net cash flow from operating activities reached ¥524,218,863.43, up 28.42% from ¥408,218,063.31 in the previous year[12]. - The basic earnings per share for 2022 was ¥0.8035, a 44.96% increase from ¥0.5543 in 2021[12]. - The total assets at the end of 2022 amounted to ¥7,982,324,465.77, reflecting a 12.62% increase from ¥7,087,797,976.53 at the end of 2021[12]. - The company reported a weighted average return on equity of 8.90% for 2022, compared to 7.03% in 2021[12]. - In 2022, the company achieved a revenue of CNY 2,405.19 million, representing a year-on-year growth of 21.98%[32]. - The net profit attributable to shareholders reached CNY 587.13 million, with a significant increase of 50.14% year-on-year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 517.57 million, showing a remarkable growth of 99.39%[32]. - Domestic market sales revenue was CNY 2,292.12 million, reflecting a year-on-year increase of 17.31%[32]. - Overseas sales revenue surged to CNY 113.06 million, marking an impressive growth of 534.38% year-on-year[32]. Market and Industry Insights - The blood products market is projected to exceed $47.7 billion globally by 2027, indicating significant growth potential for the company[18]. - The Chinese blood products market is currently valued at over ¥400 billion, with substantial growth opportunities compared to mature markets in Europe and the US[18]. - The company plans to leverage the tightening international supply of blood products to enhance domestic production and export opportunities[18]. - The blood products industry in China has a high entry barrier, with only 28 qualified production enterprises as of now[20]. - The market for blood products in China is expected to grow significantly, with potential market capacity surpassing 100 billion yuan in the future[26]. - The blood products market in China is characterized by long-term supply shortages, with strict regulations on plasma collection and imports[23]. - The industry is witnessing increasing concentration, with major players capturing over 80% of the market share globally[26]. Strategic Initiatives and Partnerships - The company plans to expand its market presence and enhance its product offerings through new technology development and strategic partnerships[3]. - The company has established a strategic cooperation agreement with Xinjiang Deyuan to supply no less than 180 tons of plasma annually for five years[27]. - The strategic partnership with Xinjiang Deyuan has strengthened plasma collection capabilities and improved supply stability[32]. - The company plans to expand its product offerings and enhance brand effects through multi-brand operations and resource integration[36]. - The company is actively pursuing overseas market registration and export opportunities in Southeast Asia, South America, and the Middle East[32]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[97]. Research and Development - The company has a total of 71 authorized patents and is actively developing over 10 products, indicating strong R&D capabilities[35]. - The company is currently in the clinical trial phase for several new blood product lines, aiming to enhance its product offerings and profitability[50]. - The company plans to submit applications for drug registration for several new products, which are expected to enhance its core competitiveness and profit margins[51]. - The company has over 10 products in the rapid development stage, including human prothrombin complex, which is expected to obtain production licensing soon[76]. - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[158]. Governance and Management - The company has established a strong governance structure with experienced board members overseeing its operations[96]. - The company maintained independence from its controlling shareholders in personnel, assets, finance, institutions, and business operations[89]. - The company has a complete and clear ownership of its operational assets, including production equipment and intangible assets[89]. - The company has a robust human resources management system, including independent salary management and accounts[89]. - The company has a management method for subsidiaries to ensure standardized and efficient operations[138]. - The company has a management team with extensive experience in finance and pharmaceuticals, including positions at major financial institutions and pharmaceutical companies[96][97][98]. Financial Management and Audit - The company engaged KPMG Huazhen LLP as its accounting firm for the reporting period[10]. - The audit fee for KPMG Huazhen LLP was CNY 2.2 million for the reporting period[165]. - The total audit fee for the 2022 financial report and internal control audit was RMB 2.2 million, with RMB 1.65 million for the financial report audit and RMB 0.55 million for the internal control audit[169]. - The company maintains an independent financial accounting department and decision-making process[160]. - The company has committed to avoiding or minimizing related party transactions to protect shareholder interests[160]. Shareholder and Dividend Information - The company reported a cash dividend of 0.80 RMB per 10 shares, based on a total of 732,642,692 shares, with no stock bonus issued[2]. - The company’s unallocated profit for the 2022 fiscal year is 1,286,639,844.36 yuan, with 217,808,572.53 yuan available for distribution to shareholders[126]. - The company’s cash dividend distribution accounted for 100% of the total profit distribution amount[126]. - The company has not proposed any cash dividend distribution plan for the previous fiscal year despite having positive distributable profits[125]. Compliance and Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[2]. - The company is committed to adhering to legal regulations and enhancing internal controls to mitigate risks and ensure sustainable development[84]. - The blood products industry faces regulatory risks due to stringent government oversight and evolving policies, which may impact competition and operations[80]. - The company acknowledges the inherent risks in product development, particularly in the innovative biopharmaceutical sector, where high investment and long cycles are common[83]. Social Responsibility and Environmental Initiatives - The company actively participates in social welfare initiatives, including donations for poverty alleviation and healthcare support for patients with hemophilia[152]. - The company has committed to achieving a net profit of no less than RMB 75 million, 120 million, 180 million, and 220 million for the years 2020, 2021, 2022, and 2023 respectively[156]. - The company has received recognition as an advanced unit in legal awareness activities, reflecting its commitment to corporate social responsibility[152]. - The company has implemented environmental protection measures, including wastewater treatment and emissions monitoring, ensuring compliance with regulations[145].

Financial Performance - The company's operating revenue for Q1 2023 was ¥260,860,262.39, a decrease of 47.87% compared to ¥500,420,632.99 in the same period last year[5] - Net profit attributable to shareholders was ¥56,376,087.53, down 46.62% from ¥105,604,403.84 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥36,249,382.73, a decline of 59.73% compared to ¥90,018,691.14 in the previous year[5] - Basic earnings per share decreased to ¥0.0771, down 46.68% from ¥0.1446 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 260,860,262.39, a decrease of 47.9% compared to CNY 500,420,632.99 in the same period last year[18] - The net profit for Q1 2023 was CNY 56,218,316.92, a decrease of 47.1% compared to CNY 106,003,691.20 in the same period last year[19] - Total comprehensive income for Q1 2023 was CNY 56,209,176.61, down 47.1% from CNY 106,009,588.72 in Q1 2022[19] - The total operating profit for Q1 2023 was CNY 63,173,481.12, down 47.4% from CNY 120,103,775.12 in Q1 2022[19] Cash Flow and Assets - The company's cash flow from operating activities increased by 36.56% to ¥106,564,727.56 from ¥78,037,892.32 in the same period last year[5] - Cash flow from operating activities increased to CNY 562,858,056.37, compared to CNY 475,536,500.26 in the previous year, marking a growth of 18.4%[21] - The company's cash and cash equivalents decreased to ¥973,510,301.00 from ¥1,000,797,127.67 at the beginning of the year, a decline of approximately 2.9%[14] - The cash and cash equivalents at the end of Q1 2023 amounted to CNY 973,237,430.92, a decrease from CNY 1,000,270,509.13 at the beginning of the quarter[22] - Total assets at the end of the reporting period were ¥7,925,830,728.13, a slight decrease of 0.71% from ¥7,982,324,465.77 at the end of the previous year[5] - Total current assets decreased to ¥2,985,750,503.88 from ¥3,046,975,789.60, a decline of about 2%[14] - Total liabilities decreased to CNY 1,000,750,529.04 in Q1 2023 from CNY 1,121,197,229.65 in the previous quarter, representing a reduction of 10.8%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period was 23,607[10] - The largest shareholder, Hangzhou Zhemin Investment Partnership, holds 18.35% of shares, totaling 134,464,531 shares[10] - The equity attributable to shareholders increased by 0.92% to ¥6,930,934,944.53 from ¥6,867,524,210.96 at the end of the previous year[5] - The company's equity attributable to shareholders increased to CNY 6,930,934,944.53 from CNY 6,867,524,210.96, reflecting a growth of 0.9%[16] Operational Changes - The company reported a significant increase in other income, which rose by 158.96% to ¥5,208,458.90 due to increased government subsidies[8] - The company experienced a 44.39% improvement in net cash flow from investing activities, which was -¥171,669,347.44 compared to -¥308,715,589.61 in the previous year[8] - The company reported a 175.66% increase in notes receivable, totaling ¥103,663,605.34, primarily due to an increase in commercial bills received during the period[8] - The company has announced a strategic cooperation with Xinjiang Deyuan, indicating plans for future market expansion[12] - The company is in the process of establishing an investment fund in collaboration with professional investment institutions, reflecting a new strategic direction[12] - The company has initiated a share repurchase program, demonstrating confidence in its long-term value[12] Cost and Expenses - Total operating costs for Q1 2023 were CNY 218,309,593.81, down 43.2% from CNY 384,458,625.31 year-over-year[18] - R&D expenses for Q1 2023 were CNY 14,274,385.64, slightly down from CNY 14,574,604.59 in the previous year[18] - The company incurred credit impairment losses of CNY 12,061,663.28 in Q1 2023, compared to a gain of CNY -452,725.42 in the previous year[19] Inventory and Receivables - Trade receivables decreased significantly to ¥460,878,023.27 from ¥835,877,041.68, representing a reduction of about 45%[14] - Inventory increased to ¥788,805,196.76 from ¥623,689,205.55, marking an increase of approximately 26.5%[14] - The company reported a significant increase in trading financial assets, rising to ¥495,663,687.51 from ¥422,435,301.19, an increase of approximately 17.3%[14]

证券代码：000403 证券简称：派林生物 公告编号：2023-027 派斯双林生物制药股份有限公司 关于举行2022年度业绩说明会的公告 （http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次说明会。 二、征集问题事项 为提升交流的针对性和有效性，以便公司在本次说明会上对投资者普遍关注的问 题进行作答，公司现就本次说明会提前向投资者公开征集问题，广泛听取投资者的意 见和建议。投资者可提前登录"互动易"平台，进入"业绩说明会提问预征集"界面 （http://irm.cninfo.com.cn/interview/collect/questionCollect），输入公司股 票代码后进行提问。届时公司将在本次说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与。 特此公告。 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在 巨潮资讯网（http://www.cninfo.com.cn）上披露了《派斯双林生物制药股份有限公 司 2022 ...